Skip to content
lifestyle.successxl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HCW Biologics Inc.
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
June 16, 2026
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
May 27, 2026
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
May 22, 2026
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
May 14, 2026
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
May 14, 2026
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
April 30, 2026
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
April 29, 2026
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
February 13, 2026
←
Previous Page
1
2